SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Home
/
update
/
details

Beckman Coulter and Illumina Streamline Oncology Research with New Automated Genomic Profiling Solution

NextEdge Admin

09 Aug 2024

1 min 47 sec

Beckman Coulter Life Sciences and Illumina have introduced a new automated solution for oncology research, integrating the Illumina TruSight™ Oncology 500 DNA/RNA assay with the Biomek NGeniuS System. This collaboration streamlines comprehensive genomic profiling of tumor samples, supporting both DNA and RNA inputs to detect key cancer biomarkers like SNVs, gene amplifications, and fusions. The system enables complete library preparation in under three days, significantly reducing manual work and enhancing precision.

The Biomek NGeniuS System can process four to 24 libraries in a single batch, accommodating both high and low-quality FFPE samples. The assay is designed to reduce plastic use and lower consumable costs, promoting sustainability in cutting-edge research.

Ewan Grant of Beckman Coulter highlighted the importance of delivering faster, more reliable data, while Illumina’s Mike Kreitzinger emphasized the system's ability to reduce hands-on time and improve the user experience. Launched in June 2022, the Biomek NGeniuS System is optimized for low-medium throughput NGS library preparation, minimizing user errors and manual interventions in the process. This collaboration continues the companies' efforts to advance automated solutions in clinical oncology research.